Chiasma Inc CHMA has announced new data from the MPOWERED Phase 3 trial of Mycapssa as the first oral therapy to treat acromegaly.
- Chiasma presented the data at the Endocrine Society's annual meeting.
- The data from MPOWERED showed that Mycapssa improved clinical symptoms and other patient-reported outcomes compared to long-acting injectable somatostatin receptor ligands (iSRLs) in patients with acromegaly.
- Additionally, Mycapssa met the pre-specified non-inferiority margin compared to long-acting iSRLs in the maintenance of biochemical response.
- Data showed that Mycapssa demonstrated non-inferiority to iSRLs in maintaining a biochemical response; 91% of the Mycapssa patients maintained insulin-like growth factor 1 (IGF-1) response.
- The overall mean symptom score decreased from 4.5 to 3.5; the mean change from baseline was statistically significant and clinically meaningful.
- Overall, 80.4% of the randomized patients maintained or improved their symptoms score during the run-in phase compared to baseline.
- At the end of the RCT phase, 15% of patients reported breakthrough acromegaly symptoms in the octreotide capsules group and 31% of patients in the iSRLs group.
- Adverse event incidence and nature were similar to the known octreotide safety profile and acromegaly disease burden.
- Price Action: CHMA shares are trading 3.8% higher at $3.54 in the premarket on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in